Granules India Limited

Granules India Limited

Granules India Limited has submitted a Paragraph IV certification for its ANDA for Ruxolitinib Extended-Release Tablets, which may make it eligible for first-to-file status and 180 days of generic drug exclusivity in the US.

Granules India Limited

Granules India Limited has informed the Exchange about the transcript of the webinar held on September 29, 2026, where the company's management discussed its growth strategy, product strategy, and R&D priorities.

Granules India Limited

Granules India Limited has informed the Exchange about the incorporation of a wholly owned foreign subsidiary, TRITON FARMACEUTICA DO BRASIL LTDA, in Brazil.

Granules India Limited

Granules India Limited has informed the Exchange about the link of the recording of the webinar held on September 29, 2026, which has been uploaded on the company's website.

Granules India Limited

Granules India Limited has informed the Exchange about a scheduled webinar on September 29, 2026, to discuss the company's transformation journey and growth prospects.

Granules India Limited

Granules India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Granules India Limited

Granules India Limited has informed the Exchange about the schedule of an Analyst/Investor Meeting to be held on September 28, 2026, at New Delhi. The meeting is subject to changes and no unpublished price-sensitive information will be shared.

Granules India Limited

Granules India Limited has informed the Exchange about the allotment of 2,49,82,906 equity shares of face value of Re. 1/- each to the members of the Promoter Group investor category, as detailed in Annexure I (A), upon conversion of warrants.

Granules India Limited

Granules India Limited has informed the Exchange regarding the receipt of the balance subscription amount towards the conversion of warrants issued on a private placement basis, strengthening its net cash position.

Granules India Limited

Granules India Limited has informed the Exchange regarding a change in shareholding of the Promoter and Promoter Group. Dr. Krishna Prasad Chigurupati, the Promoter, sold 1,72,00,000 equity shares through a block deal and open market. The transaction was undertaken to fund the second tranche of the Company’s ongoing preferential issue and support the next phase of growth initiatives.

Granules India Limited

Granules India Limited has informed the Exchange about the schedule of an analyst/investor meeting on September 18, 2026, in Hyderabad. The meeting is tentative and subject to changes due to difficulties from the Company or Analyst/Investor/Funds. No unpublished price-sensitive information is proposed to be shared by the Company during the meetings.

Granules India Limited

Granules India Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Granules India Limited

Granules India Limited has informed the Exchange about the change in management, with Mr. Sanjay Kumar, Chief Strategy Officer, transferring to a wholly-owned subsidiary, Ascelis Peptides Private Limited, as its CEO, effective August 13, 2026.

Granules India Limited

Granules India Limited has held its 35th Annual General Meeting (AGM) on August 06, 2026, where the company's financial statements for FY 2025-26 were adopted, a final dividend of Rs. 1.75 paise per equity share was declared, and Ms. Priyanka Chigurupati was re-appointed as an Executive Director.

Granules India Limited

Granules India Limited has announced its Q1 FY27 financial results, with revenue growing 22% to INR1,477 crores, gross margin at 65.6%, EBITDA growing 37% to INR339 crores, and profit after tax growing 60% to INR180 crores. The company has also highlighted its return on capital, which has improved to 18%, and its net debt to EBITDA ratio is now 0.07x, making it debt-free for all practical purposes.

Granules India Limited

Granules India Limited has informed the Exchange about the link of recording for the Analysts/Institutional Investor Meet/Con. Call Updates. The recording is available on the company's website.

Granules India Limited

Granules India Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026 regarding the utilization of proceeds from its preferential issue of equity shares completed in February 2026. The report, issued by India Ratings & Research, confirms no deviation from the stated objects of the issue, based on management undertakings and a statutory auditor certificate. The filing is made pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. No adverse findings were noted, and the report is being submitted to NSE and BSE for record.

Granules India Limited

Granules India Limited notified the National Stock Exchange that it will share a presentation related to an analysts/institutional investor meet or conference call. The announcement does not disclose any specific financial results, strategic initiatives, or other material information. It is a routine procedural update regarding investor communication.

Granules India Limited

Granules India Limited announced its unaudited financial results for Q1 FY27, reporting revenue from operations of INR 14,768 million, a 22% year‑on‑year increase. EBITDA rose to INR 3,389 million (+37% YoY) and profit after tax reached INR 1,800 million (+60% YoY). Net debt declined sharply to INR 1,012 million, reducing the net debt‑to‑EBITDA ratio to 0.07x, while ROCE improved to 18.0%. The company highlighted strong performance across its API, finished dosage, PFI and peptides CDMO segments and reiterated focus on regulatory excellence and portfolio transformation.

Granules India Limited